Dianthus Therapeutics, Inc. (NASDAQ:DNTH – Get Free Report) SVP Adam Veness sold 16,167 shares of Dianthus Therapeutics stock in a transaction on Monday, August 10th. The shares were sold at an average price of $110.38, for a total value of $1,784,513.46. Following the completion of the transaction, the senior vice president owned 3,833 shares of the company’s stock, valued at approximately $423,086.54. This trade represents a 80.84% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.
Dianthus Therapeutics Stock Down 3.0%
Shares of NASDAQ:DNTH traded down $3.31 during midday trading on Tuesday, reaching $108.49. 777,875 shares of the company traded hands, compared to its average volume of 972,407. The firm’s fifty day moving average price is $95.17 and its two-hundred day moving average price is $81.36. The firm has a market capitalization of $5.93 billion, a price-to-earnings ratio of -26.14 and a beta of 1.22. Dianthus Therapeutics, Inc. has a 12 month low of $19.00 and a 12 month high of $114.55.
Dianthus Therapeutics (NASDAQ:DNTH – Get Free Report) last issued its earnings results on Tuesday, August 4th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.85) by ($0.05). The company had revenue of $0.76 million during the quarter, compared to the consensus estimate of $0.30 million. Dianthus Therapeutics had a negative return on equity of 22.53% and a negative net margin of 10,096.95%. Analysts forecast that Dianthus Therapeutics, Inc. will post -3.83 earnings per share for the current year.
Hedge Funds Weigh In On Dianthus Therapeutics
Analyst Upgrades and Downgrades
A number of research firms recently weighed in on DNTH. HC Wainwright upped their target price on shares of Dianthus Therapeutics from $130.00 to $158.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Wedbush boosted their price target on shares of Dianthus Therapeutics from $105.00 to $122.00 and gave the company an “outperform” rating in a research report on Wednesday, August 5th. Wall Street Zen upgraded Dianthus Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of Dianthus Therapeutics in a research note on Friday, July 17th. Finally, Wolfe Research restated an “outperform” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $124.27.
Check Out Our Latest Research Report on Dianthus Therapeutics
About Dianthus Therapeutics
Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.
Read More
- Five stocks we like better than Dianthus Therapeutics
- Atlassian Just Pulled Off the Software Comeback Wall Street Wanted
- AST SpaceMobile Earnings Just Reminded Investors How Risky Space Can Be
- NVIDIA’s Rally Sets Up a Bigger Test Ahead of Earnings
- Apple’s Next iPhone Could Test How Much Pricing Power Is Left
Receive News & Ratings for Dianthus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dianthus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
